mTOR: Role in cancer, metastasis and drug resistance

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · see citing works

Epithelial–mesenchymal transitions in tumour progression

Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,632 · see citing works

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · see citing works

Rho GTPases and the Actin Cytoskeleton

Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,138 · see citing works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · see citing works

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645 · see citing works

Targeting RAS signalling pathways in cancer therapy

Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,262 · see citing works

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · see citing works

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083 · see citing works

Patterns of somatic mutation in human cancer genomes

Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062 · see citing works

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

Alessi, D., James, S., Downes, C., Holmes, A. B., Gaffney, P., Reese, C., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 3,047 · see citing works

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · see citing works

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879 · see citing works

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · see citing works

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665 · see citing works

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,659 · see citing works

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097 · see citing works

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · see citing works

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,010 · see citing works

Phosphatidylinositol-3-OH kinase direct target of Ras

Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954 · see citing works

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886 · see citing works

DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717 · see citing works

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691 · see citing works

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · see citing works

RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509 · see citing works

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,391 · see citing works

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes &amp; Development · doi:10.1101/gad.1256804 · Cited by 1,384 · see citing works

mTOR and cancer: insights into a complex relationship

Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · see citing works

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313 · see citing works

FOXO transcription factors at the interface between longevity and tumor suppression

Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,306 · see citing works

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,288 · see citing works

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · see citing works

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250 · see citing works

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · see citing works

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199 · see citing works

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173 · see citing works

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,139 · see citing works

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134 · see citing works

mTOR signalling and cellular metabolism are mutual determinants in cancer

Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088 · see citing works

The mTOR‐regulated phosphoproteome reveals a mechanism of mTORC1‐mediated inhibition of growth factor signaling

Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084 · see citing works

mTOR kinase structure, mechanism and regulation

Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075 · see citing works

PKB/Akt

Lawlor, M. A., & Alessi, D. R. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.16.2903 · Cited by 1,071 · see citing works

mTOR as a central hub of nutrient signalling and cell growth

Kim, J., & Guan, K. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0205-1 · Cited by 1,067 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991 · see citing works

Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells

Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887 · see citing works

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Белоусова, Е. Д., Sauter, M., Nonomura, N., Brakemeier, S., de Vries, P. J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61767-x · Cited by 880 · see citing works

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 855 · see citing works

PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

Corless, C. L., Schroeder, A., Griffith, D., Town, A., McGreevey, L. S., Harrell, P. M., Shiraga, S., Bainbridge, T., Morich, J. R., & Heinrich, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.068 · Cited by 848 · see citing works

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 813 · see citing works

Autophagy as a target for anticancer therapy

Jankú, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 803 · see citing works

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T. C., Cosulich, S. C., Critchlow, S. E., Vincent, J. P., Ellston, R. P. A., Jones, D., Sini, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 796 · see citing works

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794 · see citing works

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas

Cappellen, D., de Oliveira, C. C. B., Ricol, D., de Medina, S. D., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 743 · see citing works

eIF-4E expression and its role in malignancies and metastases

Benedetti, A. D., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728 · see citing works

A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., & Abraham, R. T. (2000) · PubMed · Cited by 712 · see citing works

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · see citing works

Control of p70 S6 kinase by kinase activity of FRAP in vivo

Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705 · see citing works

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al‐Ahmadie, H. A., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 688 · see citing works

Class I PI3K in oncogenic cellular transformation

Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 598 · see citing works

Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control.

Oldham, S., & Hafen, E. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)00042-9 · Cited by 574 · see citing works

Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

Lamouille, S., & Derynck, R. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611146 · Cited by 573 · see citing works

Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation.

Rodriguez‐Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., & Downward, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00602.x · Cited by 565 · see citing works

Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.

Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556 · see citing works

Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40

Yang, H., Jiang, X., Li, B., Yang, H. J., Miller, M., Yang, A., Dhar, A., & Pavletich, N. P. (2017) · Nature · doi:10.1038/nature25023 · Cited by 548 · see citing works

mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways

Gulhati, P., Bowen, K. A., Liu, J., Stevens, P. D., Rychahou, P. G., Chen, M., Lee, E. Y., Weiss, H. L., O’Connor, K. L., Gao, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4058 · Cited by 544 · see citing works

Regulation of eIF-4E BP1 Phosphorylation by mTOR

Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K. I., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 529 · see citing works

Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy

Lim, J. S., Kim, W.-I., Kang, H., Kim, S. H., Park, A. H., Park, E. K., Cho, Y., Kim, H. M., Kim, J. A., Kim, J. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3824 · Cited by 524 · see citing works

PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints

Keith, C. T., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.270.5233.50 · Cited by 521 · see citing works

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479 · see citing works

Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance

Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010) · Neoplasia · doi:10.1593/neo.10688 · Cited by 466 · see citing works

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465 · see citing works

Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer

Davies, H. R., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G. R., Teague, J. W., Butler, A. P., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 464 · see citing works

Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1

Sofer, A., Lei, K., Johannessen, C. M., & Ellisen, L. W. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5834-5845.2005 · Cited by 449 · see citing works

Twenty-five years of mTOR: Uncovering the link from nutrients to growth

Sabatini, D. (2017) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1716173114 · Cited by 448 · see citing works

mTOR in aging, metabolism, and cancer

Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 446 · see citing works

mTORC1 and mTORC2 in cancer and the tumor microenvironment

Kim, L. C., Cook, R. S., & Chen, J. (2016) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 443 · see citing works

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442 · see citing works

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

Julien, L.-A., Carriere, A., Moreau, J., & Roux, P. P. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-09 · Cited by 433 · see citing works

A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity

Grabiner, B., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A. A., Beck, A. H., & Sabatini, D. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 418 · see citing works

Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors

Wagner, A. J., Malinowska-Kołodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D. �., Vena, N., Ligon, A. H., Antonescu, C. R., Ramaiya, N. H., Demetri, G. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2981 · Cited by 399 · see citing works

PtdIns(3,4,5) P 3-Dependent Activation of the mTORC2 Kinase Complex

Liu, P., Gan, W., Chin, Y. R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L. C., Toker, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0460 · Cited by 385 · see citing works

Untitled work

(1992) · PubMed · Cited by 383 · see citing works

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing

Kunstman, J. W., Juhlin, C. C., Goh, G., Brown, T. C., Stenman, A., Healy, J. M., Rubinstein, J. C., Choi, M., Kiss, N. B., Nelson-Williams, C. J., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu749 · Cited by 364 · see citing works

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

Pollock, P., Gartside, M., Dejeza, L., Powell, M., Mallon, M. A., Davies, H., Mohammadi, M., Futreal, P., Stratton, M. R., Trent, J., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210529 · Cited by 346 · see citing works

Architecture of human mTOR complex 1

Aylett, C. H. S., Sauer, E., Imseng, S., Boehringer, D., Hall, M. N., Ban, N., & Maier, T. (2016) · Science · doi:10.1126/science.aaa3870 · Cited by 344 · see citing works

Drug-sensitive FGFR2 mutations in endometrial carcinoma

Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 342 · see citing works

The TOR pathway comes of age

Stanfel, M. N., Shamieh, L. S., Kaeberlein, M. R., & Kennedy, B. K. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.007 · Cited by 339 · see citing works

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

Carrière, A., Cargnello, M., Julien, L.-A., Gao, H., Bonneil, É., Thibault, P., & Roux, P. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.07.078 · Cited by 332 · see citing works

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Wagle, N., Grabiner, B. C., Allen, E. M. V., Amin‐Mansour, A., Taylor-Weiner, A. N., Rosenberg, M. W., Gray, N. S., Barletta, J. A., Guo, Y., Swanson, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321 · see citing works

TGF-β-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasion

Lamouille, S., Connolly, E. C., Smyth, J. W., Akhurst, R. J., & Derynck, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.095299 · Cited by 310 · see citing works

Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial

Davies, D. M., de Vries, P. J., Johnson, S. R., McCartney, D. L., Cox, J. A., Serra, A. L., Watson, P., Howe, C. J., Doyle, T., Pointon, K. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0445 · Cited by 305 · see citing works

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Bärlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y.-D., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., et al. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1252 · Cited by 305 · see citing works

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289 · see citing works

Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma

Li, Y. Y., Hanna, G. J., Laga, A. C., Haddad, R. I., Lorch, J. H., & Hammerman, P. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1773 · Cited by 288 · see citing works

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Wagle, N., Grabiner, B. C., Allen, E. M. V., Hodis, E., Jacobus, S. J., Supko, J. G., Stewart, M. L., Choueiri, T. K., Gandhi, L., Cleary, J. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0353 · Cited by 281 · see citing works

Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer

Meyer, K. B., Maia, A.-T., O’Reilly, M., Teschendorff, A. E., Chin, S., Caldas, C., & Ponder, B. A. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060108 · Cited by 280 · see citing works

Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.

Jang, J., Shin, K., & Park, J.-G. (2001) · PubMed · Cited by 275 · see citing works

Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis

Zhou, H., & Huang, S.-L. (2011) · Current protein and peptide science · doi:10.2174/138920311795659407 · Cited by 273 · see citing works

4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications

Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. M., & y Cajal, S. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 272 · see citing works

Wide spectrum of developmental brain disorders from megalencephaly to focal cortical dysplasia and pigmentary mosaicism caused by mutations of MTOR

Mirzaa, G., Campbell, C., Solovieff, N., Goold, C. P., Jansen, L., Menon, S., Timms, A., Conti, V., Biag, J., Adams, C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0363 · Cited by 246 · see citing works

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245 · see citing works

A comprehensive map of the mTOR signaling network

Caron, É., Ghosh, S., Matsuoka, Y., Ashton‐Beaucage, D., Therrien, M., Lemieux, S., Perreault, C., Roux, P. P., & Kitano, H. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.108 · Cited by 241 · see citing works

TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin

Lorenz, M. C., & Heitman, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27531 · Cited by 238 · see citing works

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

Jankú, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M. T., Moulder, S., Lee, J. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.035 · Cited by 237 · see citing works

Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer

Gelsi‐Boyer, V., Orsetti, B., Cervera, N., Finetti, P., Sircoulomb, F., Rougé, C., Lasorsa, L., Letessier, A., Ginestier, C., Monville, F., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0128 · Cited by 237 · see citing works

Tor Kinases Are in Distinct Membrane-associated Protein Complexes inSaccharomyces cerevisiae

Wedaman, K. P., Reinke, A. W., Anderson, S., Yates, J. R., McCaffery, J. M., & Powers, T. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-09-0609 · Cited by 232 · see citing works

PIK3CA/PTEN Mutations and Akt Activation as Markers of Sensitivity to Allosteric mTOR inhibitors

Meric-Bernstam, F., Akcakanat, A., Chen, H.-Q., Do, K., Sangai, T., Adkins, F. C., González-Angulo, A., Rashid, A., Crosby, K., Dong, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2123 · Cited by 228 · see citing works

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

McKay, J., Murray, L. J., Curran, S., Ross, V. G., Clark, C., Murray, G. I., Cassidy, J., & McLeod, H. L. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00234-4 · Cited by 220 · see citing works

PIK3CA in cancer: The past 30 years

Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 218 · see citing works

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 214 · see citing works

Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors

Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211 · see citing works

Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction

Corvera, S. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01366-x · Cited by 206 · see citing works

SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling

Blattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204 · see citing works

Prostate cancer, PI3K, PTEN and prognosis

Wise, H. M., Hermida, M. A., & Leslie, N. R. (2017) · Clinical Science · doi:10.1042/cs20160026 · Cited by 203 · see citing works

RTP801 Is Elevated in Parkinson Brain Substantia Nigral Neurons and Mediates Death in Cellular Models of Parkinson's Disease by a Mechanism Involving Mammalian Target of Rapamycin Inactivation

Malagelada, C., Ryu, E. J., Biswas, S. C., Jackson-Lewis, V. R., & Greene, L. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3292-06.2006 · Cited by 189 · see citing works

Mechanisms of FGFR-mediated carcinogenesis

Ahmad, I., Iwata, T., & Leung, H. Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.004 · Cited by 185 · see citing works

Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb

Nakashima, M., Saitsu, H., Takei, N., Tohyama, J., Kato, M., Kitaura, H., Shiina, M., Shirozu, H., Masuda, H., Watanabe, K., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24444 · Cited by 184 · see citing works

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma

Fan, Q.-W., Aksoy, O., Wong, R. A., Ilkhanizadeh, S., Novotny, C. J., Gustafson, W. C., Truong, A. Y.-Q., Cayanan, G., Simonds, E. F., Haas-Kogan, D. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.014 · Cited by 184 · see citing works

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumorsPreprint

Robbins, C. M., Tembe, W. A., Baker, A. S., Sinari, S. A., Moses, T. Y., Beckstrom‐Sternberg, S. M., Beckstrom-Sternberg, J., Barrett, M. T., Long, J. P., Chinnaiyan, A. M., et al. (2010) · Genome Research · doi:10.1101/gr.107961.110 · Cited by 179 · see citing works

Caffeine Targets TOR Complex I and Provides Evidence for a Regulatory Link between the FRB and Kinase Domains of Tor1p

Reinke, A. W., Chen, J. C.-Y., Aronova, S., & Powers, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603107200 · Cited by 179 · see citing works

Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins

Schreiber, K. H., Ortiz, D., Academia, E. C., Anies, A. C., Liao, C., & Kennedy, B. K. (2015) · Aging Cell · doi:10.1111/acel.12313 · Cited by 177 · see citing works

Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas

Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O. V., Lévy, S., Busam, D., Li, K., Edwards, J. B., Eberhart, C. G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507200102 · Cited by 160 · see citing works

TORC2 Structure and Function

Gaubitz, C., Prouteau, M., Kuśmider, B., & Loewith, R. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.04.001 · Cited by 160 · see citing works

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

van Rhijn, B. V., van Tilborg, A. V., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J., van der Kwast, T., Zwarthoff, E., & Radvanyi, F. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200883 · Cited by 155 · see citing works

The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2

Kovalski, J. R., Bhaduri, A., Zehnder, A. M., Neela, P. H., Che, Y., Wozniak, G. G., & Khavari, P. A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.001 · Cited by 154 · see citing works

Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations

Roumiantsev, S., Krause, D. S., Neumann, C. A., Dimitri, C. A., Asiedu, F., Cross, N. C. P., & Etten, R. A. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00053-4 · Cited by 152 · see citing works

PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth

Sharma, N., Nanta, R., Sharma, J. P., Gunewardena, S., Singh, K. P., Shankar, S., & Srivastava, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5055 · Cited by 151 · see citing works

Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit

Chan, T. O., Rodeck, U., Chan, A. M.-L., Kimmelman, A. C., Rittenhouse-Simmons, S., Panayotou, G., & Tsichlis, P. N. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00033-8 · Cited by 148 · see citing works

mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR

Yin, Y., Hua, H. M., Li, M., Liu, S., Kong, Q., Shao, T., Wang, J., Luo, Y., Wang, Q., Luo, T. L., et al. (2015) · Cell Research · doi:10.1038/cr.2015.133 · Cited by 142 · see citing works

Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells

Urano, J., Sato, T., Matsuo, T., Otsubo, Y., Yamamoto, M. P., & Tamanoi, F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608510104 · Cited by 140 · see citing works

Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy

Møller, R., Weckhuysen, S., Chipaux, M., Marsan, E., Taly, V., Bebin, E., Hiatt, S., Prokop, J., Bowling, K. M., Mei, D., et al. (2016) · Neurology: Genetics · doi:10.1212/nxg.0000000000000118 · Cited by 138 · see citing works

Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors

Zhao, J., Roth, J., Bode‐Lesniewska, B., Pfaltz, M., Heitz, P. U., & Komminoth, P. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10035 · Cited by 132 · see citing works

Vorinostat-An overview

Bubna, A. (2015) · Indian Journal of Dermatology · doi:10.4103/0019-5154.160511 · Cited by 131 · see citing works

Down‐regulation of placental mTOR, insulin/IGF‐I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon

Kavitha, J., Rosario, F. J., Nijland, M. J., McDonald, T. J., Wu, G., Kanai, Y., Powell, T. L., Nathanielsz, P. W., & Jansson, T. (2013) · The FASEB Journal · doi:10.1096/fj.13-242271 · Cited by 131 · see citing works

Cryo-EM structure of human mTOR complex 2

Chen, X., Liu, M., Tian, Y., Li, J., Qi, Y., Zhao, D., Wu, Z., Huang, M., Wong, C. C. L., Wang, H., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0029-3 · Cited by 131 · see citing works

Amplification of thePlatelet-Derived Growth Factor Receptor-A(PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features

Smith, J. S., Wang, X.-Y., Qian, J., Hosek, S. M., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.495 · Cited by 126 · see citing works

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Lindblad, O., Cordero, E., Puissant, A., Macaulay, L., Ramos, A. H., Kabir, N. N., Sun, J., Vallon‐Christersson, J., Haraldsson, K., Hemann, M. T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.41 · Cited by 125 · see citing works

CONVERSION TO RAPAMYCIN IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS: REPORT OF AN INITIAL EXPERIENCE1

Domínguez, J., Mahalati, K., KIBERD, B. A., McAlister, V. C., & MacDonald, A. S. (2000) · Transplantation · doi:10.1097/00007890-200010270-00021 · Cited by 123 · see citing works

Akt Contributes to Activation of the TRIF-Dependent Signaling Pathways of TLRs by Interacting with TANK-Binding Kinase 1

Joung, S. M., Park, Z., Rani, S., Takeuchi, O., Akira, S., & Lee, J. Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903534 · Cited by 121 · see citing works

Long noncoding RNAs: emerging players in thyroid cancer pathogenesis

Murugan, A. K., Munirajan, A. K., & Alzahrani, A. S. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0188 · Cited by 120 · see citing works

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Mahalingam, D., Medina, E. C., Esquivel, J., Espitia, C. M., Smith, S. A., Oberheu, K., Swords, R. T., Kelly, K. R., Mita, M. M., Mita, A. C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1385 · Cited by 118 · see citing works

New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases

Toffalini, F., & Demoulin, J. (2010) · Blood · doi:10.1182/blood-2010-04-279752 · Cited by 104 · see citing works

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

Xu, J., Pham, C. G., Albanese, S. K., Dong, Y., Oyama, T., Lee, C., Rodrik-Outmezguine, V. S., Yao, Z., Han, S. I., Chen, D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86120 · Cited by 97 · see citing works

4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1

Yang, H., Wang, J., Liu, M., Chen, X., Huang, M., Tan, D., Wong, C. C. L., Wang, J., Wang, J., Xu, Y., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0346-6 · Cited by 96 · see citing works

m TORC 2‐ SGK ‐1 acts in two environmentally responsive pathways with opposing effects on longevity

Mizunuma, M., Neumann‐Haefelin, E., Moroz, N., Li, Y., & Blackwell, T. K. (2014) · Aging Cell · doi:10.1111/acel.12248 · Cited by 93 · see citing works

Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.

Yagasaki, F., Wakao, D., Yokoyama, Y., Uchida, Y., MUROHASHI, I., Kayano, H., Taniwaki, M., Matsuda, A., & Bessho, M. (2001) · PubMed · Cited by 92 · see citing works

An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival

Edinger, A. L., & Thompson, C. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207738 · Cited by 91 · see citing works

mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome

Klümpen, H., Queiroz, K. C. S., Spek, C. A., van Noesel, C. J. M., Brink, H. C., de Leng, W. W. J., de Wilde, R. F., Mathus-Vliegen, E. M. H., Offerhaus, G. J. A., Alleman, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7825 · Cited by 88 · see citing works

Expression of the FGFR1 gene in human breast‐carcinoma cells

Jacquemier, J. D., Adélaı̈de, J., Parc, P., Penault-Llorca, F. M., Planche, J., deLapeyrière, O., & Birnbaum, D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590314 · Cited by 86 · see citing works

Rapalogs in cancer prevention

Blagosklonny, M. V. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.22859 · Cited by 82 · see citing works

Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Chawla, S. P., Falchook, G. S., Hong, D. S., Akçakanat, A., Chen, H., Naing, A., Fu, S., Wheler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3110 · Cited by 81 · see citing works

PIKKs — the solenoid nest where partners and kinases meet

Baretić, D., & Williams, R. L. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.11.003 · Cited by 80 · see citing works

Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR

Leventer, R. J., Scerri, T. S., Marsh, A. P. L., Pope, K., Gillies, G., Maixner, W. J., MacGregor, D. P., Harvey, A. S., Delatycki, M. B., Amor, D. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001594 · Cited by 80 · see citing works

Tor forms a dimer through an N-terminal helical solenoid with a complex topology

Baretić, D., Berndt, A., Ohashi, Y., Johnson, C. M., & Williams, R. L. (2016) · Nature Communications · doi:10.1038/ncomms11016 · Cited by 80 · see citing works

mTOR Signaling Confers Resistance to Targeted Cancer Drugs

Guri, Y., & Hall, M. N. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.006 · Cited by 80 · see citing works

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Kong, Y., Si, L., Li, Y., Wu, X., Xu, X., Dai, J., Tang, H., Ma, M., Chi, Z., Sheng, X., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1110 · Cited by 79 · see citing works

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

Ip, C. K. M., Ng, P. K., Jeong, K. J., Shao, S. H., Ju, Z., Leonard, P. G., Hua, X., Vellano, C. P., Woessner, R. D., Sahni, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06949-w · Cited by 79 · see citing works

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma

Ghosh, A. P., Marshall, C. B., Coric, T., Shim, E., Kirkman, R. L., Ballestas, M. E., Ikura, M., Bjornsti, M., & Sudarshan, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4963 · Cited by 77 · see citing works

Fibrinogen promotes malignant biological tumor behavior involving epithelial–mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma

Zhang, F., Wang, Y., Sun, P., Wang, Z.-Q., Wang, D., Zhang, D.-S., Wang, F.-H., Fu, J., Xu, R., & Li, Y. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2493-4 · Cited by 77 · see citing works

Structural Analysis and Functional Implications of the Negative mTORC1 Regulator REDD1,

Vega-Rubín-de-Celis, S., Abdallah, Z., Kinch, L. N., Grishin, N. V., Brugarolas, J., & Zhang, X. (2010) · Biochemistry · doi:10.1021/bi902135e · Cited by 76 · see citing works

Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin.

Kumabe, T., SOHMA, Y., Kayama, T., Yoshimoto, T., & Yamamoto, T. (1992) · PubMed · Cited by 75 · see citing works

FGFR3 mutations in prostate cancer: association with low-grade tumors

Hernandez, S. F., de Muga, S., Agell, L., Juanpere-Rodero, N., Esgueva, R., Lorente, J. A., Mojal, S., Serrano, S., & Lloreta, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.46 · Cited by 75 · see citing works

Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition

Zong, H., Yin, B., Zhou, H., Cai, D., Ma, B., & Xiang, Y. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3321-4 · Cited by 75 · see citing works

Genetic deregulation of the PIK3CA oncogene in oral cancer

Murugan, A. K., Munirajan, A. K., & Tsuchida, N. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.005 · Cited by 73 · see citing works

Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin

Ohne, Y., Takahara, T., Hatakeyama, R., Matsuzaki, T., Noda, M., Mizushima, N., & Maeda, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801546200 · Cited by 70 · see citing works

The prospect of precision therapy for renal cell carcinoma

Ciccarese, C., Brunelli, M., Montironi, R., Fiorentino, M., Iacovelli, R., Heng, D. Y. C., Tortora, G., & Massari, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.003 · Cited by 63 · see citing works

TRIM44 promotes proliferation and metastasis in non-small cell lung cancer via mTOR signaling pathway

Xing, Y., Meng, Q., Chen, X., Zhao, Y., Liu, W., Hu, J., Xue, F., Wang, X., & Cai, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8586 · Cited by 62 · see citing works

S6K1 Plays a Key Role in Glial Transformation

Nakamura, J. L., Garcia, E., & Pieper, R. O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6188 · Cited by 60 · see citing works

Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling

Yang, Z., Xie, H., He, D., & Li, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9873 · Cited by 59 · see citing works

BMP2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mTORC1 pathway

Wang, M.-H., Zhou, X.-M., Zhang, M.-Y., Shi, L. D., Xiao, R.-W., Zeng, L.-S., Yang, X.-Z., Zheng, X., Wang, H., & Mai, S. (2017) · Aging · doi:10.18632/aging.101230 · Cited by 58 · see citing works

Cryo-EM structure of Saccharomyces cerevisiae target of rapamycin complex 2

Karuppasamy, M., Kuśmider, B., de Oliveira, T. M., Gaubitz, C., Prouteau, M., Loewith, R., & Schaffitzel, C. (2017) · Nature Communications · doi:10.1038/s41467-017-01862-0 · Cited by 58 · see citing works

Molecular Determinants of Tumor Recurrence in The Urinary Bladder

Liang Cheng, C., Zhang, S., Davidson, D. D., MacLennan, G. T., Koch, M. O., Montironi, R., & Antonio Lopez-beltran, B. (2009) · Future Oncology · doi:10.2217/fon.09.50 · Cited by 57 · see citing works

Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198–fibroblast growth factor receptor-1 chimeric tyrosine kinase

Ren, M., Li, X., & Cowell, J. K. (2009) · Blood · doi:10.1182/blood-2009-03-212704 · Cited by 56 · see citing works

mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer

Chen, X., Cheng, H., Pan, T., Liu, Y., Yang, S., Ren, C., Huang, D., Zha, X., & Liang, C. Y. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22177 · Cited by 55 · see citing works

Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis

Arai, H., Ueno, T., Tangoku, A., Yoshino, S., Abe, T., Kawauchi, S., Oga, A., Furuya, T., Oka, M., & Sasaki, K. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00106-7 · Cited by 55 · see citing works

Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis

Lu, M., Zessin, A. S., Glover, W., & Hsu, D. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169439 · Cited by 55 · see citing works

eIF4E Phosphorylation in Prostate Cancer

D'Abronzo, L. S., & Ghosh, P. (2018) · Neoplasia · doi:10.1016/j.neo.2018.04.003 · Cited by 54 · see citing works

Exome Sequencing Reveals De Novo Germline Mutation of the Mammalian Target of Rapamycin (MTOR) in a Patient with Megalencephaly and Intractable Seizures

(2013) · Journal of Genomes and Exomes · doi:10.4137/jge.s12583 · Cited by 53 · see citing works

Folliculin regulates mTORC1/2 and WNT pathways in early human pluripotency

Mathieu, J., Detraux, D., Kuppers, D. A., Wang, Y., Cavanaugh, C., Sidhu, S. B., Levy, S., Robitaille, A. M., Ferreccio, A., Bottorff, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08020-0 · Cited by 51 · see citing works

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS- Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network

Chatterjee, S., Huang, E. H. ‐., Christie, I., Kurland, B. F., & Burns, T. F. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0677 · Cited by 50 · see citing works

A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces

Baynam, G. S., Overkov, A., Davis, M. R., Mina, K., Schofield, L., Allcock, R. J. N., Laing, N. G., Cook, M., Dawkins, H. J. S., & Goldblatt, J. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37070 · Cited by 49 · see citing works

Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway

Liu, X., Tan, X., Liu, P., Wu, Y., Qian, S., & Zhang, X. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15166223632406 · Cited by 49 · see citing works

Inhibiting 4EBP1 in Glioblastoma

Fan, Q. W., Nicolaides, T. P., & Weiss, W. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0042 · Cited by 48 · see citing works

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial–mesenchymal transition induced by hypoxia and TGF-β1

Lin, G., Gai, R., Chen, Z., Wang, Y., Liao, S., Dong, R., Zhu, H., Gu, Y., He, Q., & Yang, B. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.011 · Cited by 47 · see citing works

p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma

Wu, D., Cheng, J., Sun, G., Wu, S., Li, M., Gao, Z., Zhai, S., Li, P., Su, D., & Wang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9282 · Cited by 46 · see citing works

Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*

Murugan, A. K., Alzahrani, A. S., & Xing, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399485 · Cited by 45 · see citing works

Cell type–specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors

Hsieh, A. C., Nguyen, H. G., Wen, L., Edlind, M. P., Carroll, P. R., Kim, W. K., & Ruggero, D. (2015) · Science Signaling · doi:10.1126/scisignal.aad5111 · Cited by 42 · see citing works

Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β‐catenin‐EGFR‐PI3K‐Akt‐mTOR signaling pathway

Zhang, B., Deng, C., Wang, L., Zhou, F., Zhang, S., Kang, W., Zhan, P., Chen, J., Shen, S., Guo, H., et al. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22747 · Cited by 40 · see citing works

Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance

Liu, W., Chang, J., Liu, M., Yuan, J., Zhang, J., Qin, J., Xia, X., & Wang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17415 · Cited by 39 · see citing works

ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition

Ruicci, K. M., Pinto, N. C., Khan, M. I., Yoo, J., Fung, K., MacNeil, S. D., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.07.010 · Cited by 38 · see citing works

Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation

Toulany, M., Schickfluß, T.-A., Fattah, K. R., Lee, K. J., Chen, B. P. C., Fehrenbacher, B., Schaller, M., Chen, D. J., & Rodemann, H. P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.004 · Cited by 35 · see citing works

Identification and characterization of two novel oncogenic mTOR mutations

Murugan, A. K., Liu, R., & Xing, M. (2019) · Oncogene · doi:10.1038/s41388-019-0787-5 · Cited by 35 · see citing works

Activating Mutations in TOR Are in Similar Structures As Oncogenic Mutations in PI3KCα

Sturgill, T. W., & Hall, M. N. (2009) · ACS Chemical Biology · doi:10.1021/cb900193e · Cited by 34 · see citing works

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,996 · see citing works

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967 · see citing works

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 775 · see citing works

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 785 · see citing works

The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review

Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497 · see citing works

Metabolism of Amino Acids in Cancer

Wei, Z. C., Liu, X., Cheng, C., Yu, W., & Yi, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603837 · Cited by 439 · see citing works

Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells

Sun, Y., Berleth, N., Wu, W., Schlütermann, D., Deitersen, J., Stuhldreier, F., Berning, L., Friedrich, A., Akgün, S., Mendiburo, M. J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04306-2 · Cited by 302 · see citing works

MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway

Lou, G., Chen, L., Xia, C., Wang, W., Qi, J., Li, A., Zhao, L., Chen, Z., Zheng, M., & Liu, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1512-5 · Cited by 296 · see citing works

The Role of mTOR Signaling as a Therapeutic Target in Cancer

Popova, N. V., & Jücker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041743 · Cited by 267 · see citing works

Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products

Iksen, I., Pothongsrisit, S., & Pongrakhananon, V. (2021) · Molecules · doi:10.3390/molecules26134100 · Cited by 228 · see citing works

Targeting mTOR and Metabolism in Cancer: Lessons and Innovations

Magaway, C., Kim, E., & Jacinto, E. (2019) · Cells · doi:10.3390/cells8121584 · Cited by 225 · see citing works

Crosstalk between Sertoli and Germ Cells in Male Fertility

Wu, S., Yan, M., Ge, R., & Cheng, C. Y. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.006 · Cited by 168 · see citing works

Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer

Ou, X., Tan, Y., Xie, J., Yuan, J., Deng, X., Shao, R., Song, C., Cao, X., Xie, X., He, R., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101063 · Cited by 156 · see citing works

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136 · see citing works

The significant role of amino acid metabolic reprogramming in cancer

Liu, X., Ren, B., Ren, J., Gu, M., You, L., & Zhao, Y.-P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01760-1 · Cited by 135 · see citing works

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121 · see citing works

Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer

Ashrafizadeh, M., Bakhoda, M. R., Bahmanpour, Z., Ilkhani, K., Zarrabi, A., Makvandi, P., Khan, H. Z., Mazaheri, S., Darvish, M., & Mirzaei, H. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00829 · Cited by 114 · see citing works

CCL18 in the Progression of Cancer

Korbecki, J., Olbromski, M., & Dzięgiel, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217955 · Cited by 110 · see citing works

Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives

Mortezaee, K., & Najafi, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103180 · Cited by 106 · see citing works

Curcumin downregulates the PI3K–AKT–mTOR pathway and inhibits growth and progression in head and neck cancer cells

Borges, G. Á., Elias, S. T., Amorim, B. R., de Lima, C. L., Coletta, R. D., CASTILHO, R. M., SQUARIZE, C. H., & Guerra, E. N. S. (2020) · Phytotherapy Research · doi:10.1002/ptr.6780 · Cited by 100 · see citing works

Nanomedicine Strategies in Conquering and Utilizing the Cancer Hypoxia Environment

Pan, Y., Liu, L., Mou, X., & Cai, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07763 · Cited by 98 · see citing works

Glutamine addiction in tumor cell: oncogene regulation and clinical treatment

Li, X., Peng, X., Li, Y., Wei, S., He, G., Liu, J., Li, X., Yang, S., Dai, L., Lin, W., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01449-x · Cited by 99 · see citing works

Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma

Zhang, A., Yang, J., Ma, C., Li, F., & Luo, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.616271 · Cited by 92 · see citing works

Body fatness associations with cancer: evidence from recent epidemiological studies and future directions

Larsson, S. C., Spyrou, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155326 · Cited by 89 · see citing works

Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action

Chen, J., Wu, S., Shi, Z.-M., & Hu, B. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00719-7 · Cited by 91 · see citing works

Hepatocellular carcinoma recurrence: Predictors and management

Abdelhamed, W., & El‐Kassas, M. (2023) · Liver Research · doi:10.1016/j.livres.2023.11.004 · Cited by 84 · see citing works

Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer

Evangelisti, C., Chiarini, F., Paganelli, F., Marmiroli, S., & Martelli, A. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118635 · Cited by 80 · see citing works

Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis

Ashrafizadeh, M., Gholami, M. H., Mirzaei, S., Zabolian, A., Haddadi, A., Farahani, M. V., Kashani, S. H., Hushmandi, K., Najafi, M., Zarrabi, A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.119006 · Cited by 78 · see citing works

Emerging Roles of Liquid–Liquid Phase Separation in Cancer: From Protein Aggregation to Immune-Associated Signaling

Lu, J., Qian, J., Xu, Z., Yin, S., Zhou, L., Zheng, S., & Zhang, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.631486 · Cited by 76 · see citing works

Targeting lactate metabolism for cancer immunotherapy - a matter of precision

Heuser-Loy, C., Renner, K., Kreutz, M. P., & Gattinoni, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.001 · Cited by 76 · see citing works

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents

Occhiuzzi, M. A., Lico, G., Ioele, G., Luca, M. D., Garofalo, A., & Grande, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114971 · Cited by 75 · see citing works

Annexin A2 : The diversity of pathological effects in tumorigenesis and immune response

Huang, Y., Jia, M., Yang, X., Han, H., Hou, G., Bi, L., Yang, Y., Zhang, R., Zhao, X., Peng, C., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34048 · Cited by 74 · see citing works

Aging conundrum: A perspective for ovarian aging

Wu, J., Liu, Y., Song, Y., Wang, L., Ai, J., & Li, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.952471 · Cited by 73 · see citing works

The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?

Xu, J., Li, Y., Tang, Y., Xu, Z., Xu, H.-D., Cheng, X., & Qin, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621428 · Cited by 66 · see citing works

Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy

Cuomo, F., Altucci, L., & Cobellis, G. (2019) · Cancers · doi:10.3390/cancers11101465 · Cited by 62 · see citing works

ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance

Huang, J., Li, J., Tang, J., Wu, Y., Dai, F., Yi, Z., Wang, Y., Li, Y., Wu, Y., Ren, G., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70544 · Cited by 62 · see citing works

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04841-w · Cited by 65 · see citing works

PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?

Chen, Y., Guan, W., Wang, M., & Lin, X. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae010 · Cited by 61 · see citing works

p62-Nrf2-p62 Mitophagy Regulatory Loop as a Target for Preventive Therapy of Neurodegenerative Diseases

Gureev, A. P., Sadovnikova, I. S., Starkov, N. N., Starkov, A. A., & Popov, V. N. (2020) · Brain Sciences · doi:10.3390/brainsci10110847 · Cited by 61 · see citing works

Antioxidative Stress: Inhibiting Reactive Oxygen Species Production as a Cause of Radioresistance and Chemoresistance

Chen, Y., Li, Y., Huang, L., Du, Y., Gan, F., Li, Y., & Yao, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6620306 · Cited by 58 · see citing works

GALNT14 Regulates Ferroptosis and Apoptosis of Ovarian Cancer Through the EGFR/mTOR Pathway

Li, H.-W., Liu, M., Jiang, X., Song, T., Feng, S., Wu, J., Deng, P., & Wang, X. (2021) · Future Oncology · doi:10.2217/fon-2021-0883 · Cited by 56 · see citing works

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

Fu, W., & Wu, G. (2023) · Molecules · doi:10.3390/molecules28073157 · Cited by 58 · see citing works

Lactobacillus spp. create a protective micro-ecological environment through regulating the core fucosylation of vaginal epithelial cells against cervical cancer

Fan, Q., Wu, Y., Li, M., An, F., Yao, L., Wang, M., Wang, X., Yuan, J., Jiang, K., Li, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04388-y · Cited by 58 · see citing works

To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway

Zhong, J., Ding, S., Zhang, X., Di, W., Wang, X., Zhang, H., Chen, Y., Zhang, Y., & Hu, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802037 · Cited by 54 · see citing works

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system

Zhao, B., Fu, Y., Cui, S., Chen, X., Liu, S., & Luo, L. F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1333662 · Cited by 53 · see citing works

mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications

Lawal, B., Lee, C., Mokgautsi, N., Sumitra, M. R., Khedkar, H., Wu, A. T. H., & Huang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656738 · Cited by 52 · see citing works

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research

Son, B., Lee, W., Kim, H., Shin, H., & Park, H. H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07077-8 · Cited by 52 · see citing works

Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?

Ameer, S. F., Mohamed, M. Y., Elzubair, Q. A., Sharif, E. A. M., & Ibrahim, W. N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1438040 · Cited by 52 · see citing works

Gene Therapy Strategies Targeting Aging-Related Diseases

Yu, J., Li, T., & Zhu, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.00725 · Cited by 51 · see citing works

New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.

Hu, H., Li, B., Wang, J., Tan, Y., Xu, M., Xu, W., & Lu, H.-J. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.114778 · Cited by 44 · see citing works

Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment

Hage, A., & Dormond, O. (2021) · Cancers · doi:10.3390/cancers13061359 · Cited by 49 · see citing works

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas

Murugan, A. K., & Alzahrani, A. (2022) · British Journal of Biomedical Science · doi:10.3389/bjbs.2021.10208 · Cited by 45 · see citing works

Emerging role and therapeutic implication of mTOR signalling in intervertebral disc degeneration

Chen, H., Zhou, J., Zhang, G., Luo, Z., Li, L., & Kang, X. (2022) · Cell Proliferation · doi:10.1111/cpr.13338 · Cited by 44 · see citing works

Special issue: PI3K/Akt signaling in human cancer

Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.022 · Cited by 45 · see citing works

A natural product solution to aging and aging-associated diseases

Yang, C., Zhang, W., Dong, X., Fu, C., Yuan, J., Xu, M., Liang, Z. C., Qiu, C., & Xu, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107673 · Cited by 43 · see citing works

The dual roles of A20 in cancer

Shi, Y., Wang, X., Wang, J., Wang, X., Zhou, H., & Zhang, L. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.017 · Cited by 44 · see citing works

Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy

Huan, J., Grivas, P. D., Birch, J., & Hansel, D. E. (2022) · Cancers · doi:10.3390/cancers14061555 · Cited by 43 · see citing works

Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer

Mir, S. A., Dar, A., Alshehri, S. A., Wahab, S., Hamid, L., Almoyad, M. A. A., Ali, T., & Bader, G. N. (2023) · Pharmaceuticals · doi:10.3390/ph16071004 · Cited by 42 · see citing works

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

Huang, X., You, L., Nepovimová, E., Psotka, M., Maliňák, D., Valko, M., Sivák, L., Korábečný, J., Heger, Z., Adam, V., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2237209 · Cited by 42 · see citing works

Functional Amino Acids and Autophagy: Diverse Signal Transduction and Application

Liu, C., Ji, L., Hu, J., Zhao, Y., Johnston, L. J., Zhang, X., & Ma, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111427 · Cited by 41 · see citing works

mTOR inhibitors in targeting autophagy and autophagy-associated signaling for cancer cell death and therapy

Senapati, P. K., Mahapatra, K. K., Singh, A., & Bhutia, S. K. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189342 · Cited by 44 · see citing works

Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Pelizzaro, F., Gambato, M., Gringeri, E., Vitale, A., Cillo, U., Farinati, F., Burra, P., & Russo, F. P. (2021) · Cancers · doi:10.3390/cancers13194882 · Cited by 41 · see citing works

Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer

Chen, Y., Zhu, W., Lin, C.-Y., Yuan, Z., Li, Z.-H., & Yan, P. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s270939 · Cited by 40 · see citing works

Erianin: A phytoestrogen with therapeutic potential

Li, G., Zhang, H., Lai, H., Liang, G., Huang, J., Zhao, F., Xie, X., & Peng, C. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1197056 · Cited by 39 · see citing works

The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials

Zhang, C., Xu, S., Yin, C., Hu, S., & Liu, P. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04218-4 · Cited by 39 · see citing works

circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop

Li, X., Wang, J., Lin, W., Yuan, Q., Lu, Y., Wang, H., Chen, L., Chen, L., Dai, P., Long, H., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01600-1 · Cited by 38 · see citing works

mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models

Qiu, J., Feng, M., Yang, G., Cao, Z., Liu, Y., You, L., & Zhang, T. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216020 · Cited by 38 · see citing works

The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors

Mostafavi, S., Zalpoor, H., & Hassan, Z. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00356-2 · Cited by 37 · see citing works

Cardiovascular Risk After SARS-CoV-2 Infection Is Mediated by IL18/IL18R1/HIF-1 Signaling Pathway Axis

Zhang, L., Li, M., Wang, Z., Sun, P., Wei, S., Zhang, C., Wu, H., & Bai, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780804 · Cited by 36 · see citing works

mTOR Signaling Components in Tumor Mechanobiology

Gargalionis, A. N., Papavassiliou, K. A., Basdra, E. K., & Papavassiliou, A. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031825 · Cited by 36 · see citing works

The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma

Zhang, P., Ono, A., Fujii, Y., Hayes, C. N., Tamura, Y., Miura, R., Shirane, Y., Nakahara, H., Yamauchi, M., Uchikawa, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34247 · Cited by 35 · see citing works

Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma

Guenzle, J., Akasaka, H., Joechle, K., Reichardt, W., Venkatasamy, A., Hoeppner, J., Hellerbrand, C., Fichtner‐Feigl, S., & Lang, S. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010030 · Cited by 34 · see citing works

Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α-dependent tumor hypoxia adaptation

Liu, J., Hu, X., Feng, L., Lin, Y., Liang, S., Zhu, Z., Shi, S., & Dong, C. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01394-w · Cited by 34 · see citing works

The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma

Qi, X. (2022) · American Journal of Cancer Research · doi:10.62347/etjh6697 · Cited by 34 · see citing works

LncRNA‐MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis

Mu, X., Shen, Z., Lin, Y., Xiao, J., Xia, K., Xu, C., Chen, B., Shi, R., Zhu, A.-Y., Sun, X., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8693259 · Cited by 33 · see citing works

MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway

Cao, D., Ge, S., & Li, M. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100412 · Cited by 32 · see citing works

Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma

Riquelme, I., Pérez-Moreno, P., Mora‐Lagos, B., Ili, C., Brebi, P., & Roa, J. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076294 · Cited by 31 · see citing works

Growth or death? Control of cell destiny by mTOR and autophagy pathways

Khalil, M. I. M., Ali, M. M., Holail, J., & Houssein, M. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.10.002 · Cited by 32 · see citing works

GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells

Zhang, X., Zhang, L., Wang, B., Zhang, X., Gu, L., Guo, K., Zhang, X., & Zhou, Z. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.14.37 · Cited by 32 · see citing works

Exosomes and their roles in the chemoresistance of pancreatic cancer

Pan, Y., Tang, H., Li, Q., Chen, G., & Li, D. (2022) · Cancer Medicine · doi:10.1002/cam4.4830 · Cited by 29 · see citing works

mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus

Zhao, X., Wang, S., Wang, S., Xie, J., & Cui, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109153 · Cited by 30 · see citing works

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

Indini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 30 · see citing works

Adipocytic Glutamine Synthetase Upregulation via Altered Histone Methylation Promotes 5FU Chemoresistance in Peritoneal Carcinomatosis of Colorectal Cancer

Zhang, X., Li, Q., Du, A., Li, Y., Shi, Q., Chen, Y., Zhao, Y., Wang, B., & Pan, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.748730 · Cited by 28 · see citing works

Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3K‐Akt–mTOR pathway

Chen, H., Zhu, T., Huang, X., Xu, W.-S., Di, Z., Ma, Y., Xue, M., Bi, S., Shen, Y., Yu, Y., et al. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1041 · Cited by 27 · see citing works

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects

Cheng, D., Ge, K., Yao, X., Wang, B., Chen, R., Zhao, W., Fang, C., & Ji, M. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1209947 · Cited by 28 · see citing works

ZEA-induced autophagy in TM4 cells was mediated by the release of Ca2+ activates CaMKKβ-AMPK signaling pathway in the endoplasmic reticulum

Feng, N., Wang, B., Cai, P., Zheng, W., Zou, H., Gu, J., Yuan, Y., Liu, X., Liu, Z., & Bian, J. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.01.010 · Cited by 28 · see citing works

Protective Effects of Propofol on Rats with Cerebral Ischemia–Reperfusion Injury Via the PI3K/Akt Pathway

Chen, Y., & Li, Z. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01703-8 · Cited by 28 · see citing works

Impact of inflammation and immunotherapy in renal cell carcinoma (Review)

Shi, J., Wang, K., Xiong, Z., Yuan, C., Wang, C., Cao, Q., Huang, Y., Meng, X., Xie, K., Cheng, Z., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12135 · Cited by 28 · see citing works

Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways

Lan, J., Huang, J., Tao, X., Gao, Y., Zhang, L., Huang, W., Luo, J., Liu, C., Deng, Y., Liu, L., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17278 · Cited by 28 · see citing works

Molecular mechanisms in regulation of autophagy and apoptosis in view of epigenetic regulation of genes and involvement of liquid-liquid phase separation

Chakraborty, S., Nandi, P., Mishra, J., Niharika, N., Roy, A., Manna, S., Baral, T., Mishra, P., Mishra, P. K., & Patra, S. K. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216779 · Cited by 29 · see citing works

MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway

Su, W., Feng, B., Hu, L., Guo, X., & Yu, M. (2022) · BMC Cancer · doi:10.1186/s12885-022-09709-8 · Cited by 27 · see citing works

Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling

Luo, Y., Liu, X., Fang, L., Yu, H., Zhang, Y., Chen, M., Zhang, L.-D., & Xie, C. (2022) · Theranostics · doi:10.7150/thno.76873 · Cited by 27 · see citing works

ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export

Zhong, L., Wu, J., Zhou, B., Kang, J., Wang, X., Ye, F., & Lin, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00737-0 · Cited by 28 · see citing works

G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway

Li, R., Ke, M., Mingming, Q., Han, Z., Cao, Y., Deng, Z., Qian, J., Yang, Y., & Gu, C. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00326-6 · Cited by 26 · see citing works

mTOR (Mammalian Target of Rapamycin): Hitting the Bull’s Eye for Enhancing Neurogenesis After Cerebral Ischemia?

Gao, J., Yao, M., Chang, D., & Liu, J. (2022) · Stroke · doi:10.1161/strokeaha.122.040376 · Cited by 26 · see citing works

The roles and mechanisms of circular RNAs related to mTOR in cancers

Cao, C., Wang, Y., Wu, X., Li, Z., Guo, J., & Sun, W. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24783 · Cited by 25 · see citing works

Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis

Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., Yu, M., Irani, S., Wong, D., Merrett, J. E., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03491-1 · Cited by 26 · see citing works

Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer

Sapir, T., Shifteh, D., Pahmer, M., Goel, S., & Maitra, R. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0745 · Cited by 25 · see citing works

Targeting mTOR for cancer therapy

Hua, H., Kong, Q.-B., Zhang, H., Wang, J., Luo, T., & Jiang, Y.-F. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 772 · see citing works

Current treatment strategies for inhibiting mTOR in cancer.

Chiarini, F., Evangelisti, C., McCubrey, J., & Martelli, A. (2015) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 262 · see citing works

Tests génétiques, le cadre législatif en France et en Europe

Delpech, M. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81765-2

Polymorphisme – 493 G/T du gène de la microsomal triglycéride transfer protein et infarctus du myocarde chez une population tunisienne

Jemaa, R., Abid, M., Kallel, A., Chabrak, S., Mn, K., Elasmi, M., Feki, M., & Kaabachi, N. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81788-3

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11 · see citing works